Yoshihiko Tomita

发表

ERK5 induces ankrd1 for catecholamine biosynthesis and homeostasis in adrenal medullary cells.

W. Nemoto, P. Stork, Y. Obara, 2016, Cellular signalling.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

A. Ravaud, R. Motzer, T. Choueiri, 2015, The New England journal of medicine.

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.

C. Porta, M. Burotto, R. Motzer, 2022, The Lancet. Oncology.

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

C. Porta, M. Burotto, R. Motzer, 2022, Cancer.

accord-Long-term administration of single-agent carboplatin (AUC 4) for advanced testicular seminoma safely achieved complete response in an 80-year-old man with chronic heart failure: A case report case repOrt

Yoshihiko Tomita, Mayu Yagi, Hiroki Fukuhara, 2014 .

Advanced Bladder Cancer: Changing the Treatment Landscape

V. Bilim, Yoshihiko Tomita, Masaki Murata, 2022, Journal of personalized medicine.

Contemporary Drug Therapy for Renal Cell Carcinoma—Evidence Accumulation and Histological Implications in Treatment Strategy

Yoshihiko Tomita, R. Ohashi, K. Yamana, 2022, Biomedicines.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Significance of serum amyloid a on the prognosis in patients with renal cell carcinoma

Y. Tomita, K. Takahashi, Yoshihiko Tomita, 2001, Cancer.

Treatment of childhood renal cell carcinoma with lymph node metastasis: Two cases and a review of literature

Yoshihiko Tomita, M. Iwafuchi, M. Yagi, 2000, Journal of surgical oncology.

Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial

M. Oya, M. Fujisawa, M. Shiota, 2023, Cancer Immunology, Immunotherapy.

PD10-01 DISEASE-FREE SURVIVAL WITH LONGER FOLLOW-UP FROM THE CHECKMATE 274 TRIAL OF ADJUVANT NIVOLUMAB IN PATIENTS AFTER SURGERY FOR HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA

J. Witjes, M. Galsky, D. Bajorin, 2022, Journal of Urology.

661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

M. Burotto, R. Motzer, T. Powles, 2021, Annals of Oncology.

Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma

M. Oya, K. Tatsugami, Yoshihiko Tomita, 2023, International Journal of Clinical Oncology.

GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition

V. Bilim, O. Ichiyanagi, Yoshihiko Tomita, 2016, BMC Cancer.

Alpha‐1 adrenoceptor subtypes (high, low) in human benign prostatic hypertrophy tissue according to the affinities for prazosin

Yoshihiko Tomita, T. Mizusawa, A. Hatano, 1997, The Prostate.

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

B. Rini, V. Master, R. Uzzo, 2022, The Lancet.

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial

M. Galsky, D. Bajorin, M. Oya, 2022, Japanese journal of clinical oncology.

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial

T. Powles, T. Choueiri, A. Balar, 2022, The oncologist.

Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.

Jun Yu Li, J. Witjes, M. Galsky, 2023, European urology.

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

P. Russo, R. Motzer, B. Shuch, 2023, The Lancet.

Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER.

M. Burotto, R. Motzer, T. Choueiri, 2022, Journal of Clinical Oncology.

The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance

Takako Yamada, Yoshihiko Tomita, N. Shinohara, 2023, Japanese journal of clinical oncology.

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study

S. Anai, M. Oya, Yoshihiko Tomita, 2022, Cancer medicine.

Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC).

Jun Yu Li, M. Burotto, R. Motzer, 2023, Journal of Clinical Oncology.

Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

C. Porta, M. Burotto, R. Motzer, 2023, Journal of Clinical Oncology.

Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study

Yoshihiko Tomita, N. Nonomura, R. Mizuno, 2022, International Journal of Clinical Oncology.

Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells

V. Bilim, Yoshihiko Tomita, Masaki Murata, 2023, Current oncology.

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

A. Ravaud, R. Motzer, T. Choueiri, 2015, The New England journal of medicine.

Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.

Y. Tomita, S. Naito, Yoshihiko Tomita, 2014, Annals of Oncology.

Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study

M. Oya, M. Fujisawa, M. Shiota, 2023, International journal of urology : official journal of the Japanese Urological Association.

Hemodialysis patient with primary small cell carcinoma of the bladder treated with CPT-11 and CBDCA. Case report

O. Ichiyanagi, Yoshihiko Tomita, Hitoshi Suzuki, 2011 .

Clinical Practice Guidelines for tuberous sclerosis complex‐associated renal angiomyolipoma by the Japanese Urological Association: Summary of the update

M. Oya, Haruna Kawano, Yoshihiko Tomita, 2023, International journal of urology : official journal of the Japanese Urological Association.

Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance

T. Nakao, Yoshihiko Tomita, N. Shinohara, 2022, International Journal of Clinical Oncology.

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study

R. Motzer, M. Oya, Y. Tomita, 2017, Japanese journal of clinical oncology.